Cyclo(his-pro)

Summary

Cyclo(His-Pro) (CHP) is an endogenous cyclic dipeptide formed from the catabolism of thyrotropin-releasing hormone (TRH). It is found in the brain, gut, and peripheral tissues. It has been investigated for roles in appetite regulation, neuroprotection, glucose metabolism, and prolactin inhibition. Not approved as a therapeutic agent; primarily studied in preclinical and early clinical research contexts.

Mechanism of Action

Endogenous cyclic dipeptide derived from thyrotropin-releasing hormone (TRH) metabolism. Acts as a neuromodulator; inhibits prolactin release, modulates dopaminergic and serotonergic systems, and may influence feeding behavior via hypothalamic pathways. Also exhibits antioxidant properties and modulates glucose homeostasis.

Routes of Administration

Goals & Uses

• Prolactin inhibitionEndocrineModerate
• NeuroprotectionNeurologyLow
• Appetite and body weight regulationMetabolic / EndocrineLow
• Glucose homeostasisMetabolicLow
• Ethanol intake modulationNeurological / AddictionLow

Contraindications

• Hypersensitivity to cyclic dipeptidesAllergicHigh

Adverse Effects

• Endocrine disruptionEndocrineUnknown
• NauseaGastrointestinalUnknownFeeling of sickness or urge to vomit

Drug Interactions

• Thyrotropin-releasing hormone (TRH) analoguesLow
• Dopaminergic agentsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric populationsAgeRelative
• Patients with prolactinomas or pituitary disordersEndocrineRelative

Regulatory Status

• European UnionUnapprovedNot authorized by EMA; used only in research.
• United StatesUnapprovedNo FDA approval or registered IND for therapeutic use; research compound only.
• United KingdomUnapprovedNot authorized by MHRA; research use only.

Not approved by FDA, EMA, or other major regulatory agencies for any therapeutic indication. Used exclusively in research settings. No IND or approved clinical development program widely registered.

Evidence & Sources

No sources recorded yet.